drugset
drugset / Trial / NCT00732420

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

NCT00732420 ↗

Phase 1 Completed 68 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelScreening

Summary

To determined what dose of topotecan can be safely given with daily pazopanib.

Timeline

Start
2008-09-24
Primary completion
2013-06-12
Completion
2013-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule — Oral
Background Pazopanib Small molecule — Oral

Indications

cancer